Metabolic dysfunction-associated steatotic liver disease (MASLD): look for advanced fibrosis
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Steatosis or at-risk patient: initial tests
Fasting laboratory tests
- AST
- ALT
- FBC with platelets
- Fasting plasma glucose
- Lipid profile
- HbA1c (if fasting plasma glucose ≥ 1.26 g/L)if neededFasting plasma glucose ≥ 1.26 g/L: diabetes, HbA1c and diabetes management (grade A1) [1].
- Serum ferritinif neededA ferritin > 1 000 µg/L or a transferrin saturation > 45% leads to looking for a disease other than metabolic steatotic liver disease [1]. Cytolysis: aetiological work-up of the page "Raised transaminases".
- Transferrin saturationif neededA ferritin > 1 000 µg/L or a transferrin saturation > 45% leads to looking for a disease other than metabolic steatotic liver disease [1]. Cytolysis: aetiological work-up of the page "Raised transaminases".
- Serum creatinine with GFRif needednon-French guidelineLooking for associated kidney disease: creatinine, albuminuria and GFR are among the tests for comorbidities, at diagnosis and at follow-up [2]. Diabetic patient: see the page "Type 2 diabetes".
- Urine albumin:creatinine ratioif needednon-French guidelineLooking for associated kidney disease: creatinine, albuminuria and GFR are among the tests for comorbidities, at diagnosis and at follow-up [2]. Diabetic patient: see the page "Type 2 diabetes".
- Calculate the FIB-4 = age (years) × AST (IU/L) / [platelets (G/L) × √ALT (IU/L)].
Also consider
- Raised ALT or AST? Cytolysis requires excluding other chronic liver diseases: see the page "Raised transaminases".
- Known type 2 diabetes? For the work-up in diabetes, see the page "Type 2 diabetes".
Do not order
- Screening for steatosis in the general population: not advised [2]
- Quantifying steatosis (MRI, etc.): not recommended [1]
- Oral glucose tolerance test or fasting insulin (HOMA-IR) in routine practice: not indicated according to the AFEF [1] (EASL considers them possible, weak recommendation [2])
- Transaminases or a blood marker to diagnose NASH: no validated non-invasive method [1]
FIB-4: interpret and act
Second step, if FIB-4 ≥ 1.30 (≥ 2.0 after age 65)
- Liver elastography (FibroScan or ultrasound elastography) as first option (not a laboratory test).
- FibroTest or FibroMeter (if elastography is not available)if neededSpecialised blood marker, second line, as an alternative to elastometry, if FIB-4 does not exclude advanced fibrosis [1].
Do not order
- FibroTest, FibroMètre or elastometry first-line: start with a simple blood marker such as FIB-4 (grade B2) [1,2]; the proprietary scores are not reimbursed outside hepatitis C [5]
- NAFLD Fibrosis Score in diabetic patients: do not use it [1]
- Routine liver biopsy: reserve for cases where it changes management (doubt about another treatable cause, doubt about cirrhosis, therapeutic trial) [1]
Follow-up of steatosis without advanced fibrosis
Every 1 to 3 years (see the note)
- AST
- ALT
- FBC with platelets (new FIB-4)
Every year in prediabetes
- Fasting plasma glucoseif neededPrediabetes (fasting plasma glucose between 1.10 and 1.26 g/L): annual check of fasting plasma glucose [1].
Do not order
- Elastometry or fibrosis scores repeated every year in an F0-F2 patient: an interval of 2 to 3 years is enough [1]
Sources (7)
- Association française pour l'étude du foie (AFEF). Recommandations pour le diagnostic et le suivi non-invasif des maladies chroniques du foie (coord. V. de Lédinghen). Juillet 2020. Chapitre 4 : stéatopathie métabolique (J. Boursier).
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542 (PMID 38851997) ; co-publié dans Obes Facts. 2024;17(4):374-444.
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
- National Institute for Health and Care Excellence (NICE). Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management. NICE guideline NG49, publiée le 6 juillet 2016, dernière mise à jour le 31 juillet 2026 (recommandations 1.1 à 1.3).
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1000 à 1002 (scores biologiques de fibrose hépatique) ; absence d'acte pour le test ELF.
- Ohri S, Waterman E, Quiñones AR. Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management. Am Fam Physician. 2026;113(6):578-585.
- Akuta N, Kogiso T, Ikejima K, Otsuka M, Kawaguchi T, Kawanaka M, et al. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026 (Japanese Society of Gastroenterology, Japan Society of Hepatology). J Gastroenterol. 2026;61(6):693-710.